Track the Cullinan Therapeutics, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €1.3bn. The latest transaction was disclosed on 14 August 2026 (Cession). Among the most active insiders: Michaelson Jennifer. Every trade is free.
58
Insider Decl.
n/a
Thresholds
€6m
6 ops.
Buy Volume
€3m
34 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Cullinan Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$31.73.
45Σ signal
Buys €6m€3m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
3,480 shares@ US$9.6729.5% of flowCommon StockSEC:0001193125-25-327033:0
25 of 58 declarations
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It concentrates on the discovery and development of drugs that target specific mechanisms of the disease.